ArticleF1000Research
The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days.
Abstract read
In one paragraph
Article in F1000Research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.The Lancet. Respiratory medicine · 2023Pooled it
- Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality.Journal of clinical epidemiology · 2021Pooled it
- Reliability of Trial Information Across Registries for Trials With Multiple Registrations: A Systematic Review.JAMA network open · 2021Pooled it
- Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.Nature communications · 2021Pooled it
- Clinical trials in the Eastern Mediterranean Region: a ten-year landscape analysis.Journal of global health · 2026Article
- Characteristics of Authorized Clinical Trials in Peru, 2017-2025: A National Registry-Based Study.Therapeutic innovation & regulatory science · 2026Article
- Evaluation of consistency in adverse event reporting between trial registry and publications in COVID-19 pharmacological intervention trials.International journal of clinical pharmacy · 2026Article
- Promoting Diversity through an Understanding of Barriers and Drivers for Inclusive Clinical Trials.Therapeutic innovation & regulatory science · 2025Article
- Informed consent and trial prioritization for clinical studies during the COVID-19 pandemic. Stakeholder experiences and viewpoints.PloS one · 2024Article
- Teaching critical thinking about health information and choices in secondary schools: human-centred design of digital resources.F1000Research · 2023Article
- Characteristics and result reporting of registered COVID-19 clinical trials of Chinese and Indian traditional medicine: A comparative analysis.Frontiers in medicine · 2023Article
- Estimating the effect of COVID-19 on trial design characteristics: a registered report.Royal Society open science · 2023Article
- Randomized trials on non-pharmaceutical interventions for COVID-19: a scoping review.BMJ evidence-based medicine · 2022Article
- Review
- Clinical trial research agenda on COVID-19 - the first two years in Germany and beyond.Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen · 2022Review
- The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence.History and philosophy of the life sciences · 2022Article
- High-cited favorable studies for COVID-19 treatments ineffective in large trials.Journal of clinical epidemiology · 2022Article
- The methodology of a "living" COVID-19 registry development in a clinical context.Journal of clinical epidemiology · 2022Article
- Article
- Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study.BMJ open · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Perrine JaniaudMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.ORCID https://orcid.org/0000-0001-7684-8014
Cathrine AxforsMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Janneke Van't HooftMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Ramon SaccilottoMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Arnav AgarwalDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
Christian Appenzeller-HerzogUniversity Medical Library, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-7430-294X
Despina G Contopoulos-IoannidisDivision of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Valentin DanchevMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Ulrich DirnaglQUEST Center for Transforming Biomedical Research, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0003-0755-6119
Hannah EwaldUniversity Medical Library, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-5081-1093
Gerald GartlehnerDepartment for Evidence-based Medicine and Evaluation, Danube University Krems, Krems, Austria.
Steven N GoodmanMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.ORCID https://orcid.org/0000-0002-3872-5723
Noah A HaberMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Angeliki Diotima IoannidisMolecular Toxicology Interdepartmental Program, University of California, Los Angeles, Los Angeles, California, USA.
John P A IoannidisMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Mark P LythgoeDepartment of Surgery & Cancer, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-8952-7639
Wenyan MaDepartment of Clinical Research, University of Basel, Basel, Switzerland.
Malcolm MacleodCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Mario MaličkiMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Joerg J MeerpohlInstitute for Evidence in Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Yan MinMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
David MoherCentre for Journalology, Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Canada.ORCID https://orcid.org/0000-0003-2434-4206
Blin NagavciInstitute for Evidence in Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Florian NaudetCHU Rennes, Inserm, CIC 1414 [(Centre d'Investigation Clinique de Rennes)],, University of Rennes 1, Rennes, France.ORCID https://orcid.org/0000-0003-3760-3801
Christiane Pauli-MagnusDepartment of Clinical Research, University of Basel, Basel, Switzerland.
Jack W O'SullivanMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Nico RiedelQUEST Center for Transforming Biomedical Research, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0002-3808-1163
Jan A RothDepartment of Clinical Research, University of Basel, Basel, Switzerland.
Mandy SauermannDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Stefan SchandelmaierDepartment of Clinical Research, University of Basel, Basel, Switzerland.
Andreas M SchmittDepartment of Clinical Research, University of Basel, Basel, Switzerland.
Benjamin SpeichDepartment of Clinical Research, University of Basel, Basel, Switzerland.
Paula R WilliamsonMRC/NIHR Trials Methodology Research Partnership, University of Liverpool, Liverpool, UK.
Lars G HemkensMeta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biomedical ResearchClinical Trials as TopicCoronavirus InfectionsPandemicsPneumonia, ViralBetacoronavirusChinaCOVID-19HumansSARS-CoV-2United Statesclinical research agendaCOVID-19hydroxychloroquine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.